Skip to main content

Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC)

Publication ,  Conference
Slovin, SF; Knudsen, KE; Halabi, S; Fleming, MT; Molina, AM; Wolf, SP; de Leeuw, R; Fernandez, C; Kang, P; Southwell, T; Jones, CL; Kelly, WK ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
February 20, 2020

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

February 20, 2020

Volume

38

Issue

6

Location

San Francisco, CA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Slovin, S. F., Knudsen, K. E., Halabi, S., Fleming, M. T., Molina, A. M., Wolf, S. P., … Kelly, W. K. (2020). Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
Slovin, Susan F., Karen E. Knudsen, Susan Halabi, Mark T. Fleming, Ana M. Molina, Steven Paul Wolf, Renee de Leeuw, et al. “Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
Slovin SF, Knudsen KE, Halabi S, Fleming MT, Molina AM, Wolf SP, et al. Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2020.
Slovin, Susan F., et al. “Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 6, AMER SOC CLINICAL ONCOLOGY, 2020.
Slovin SF, Knudsen KE, Halabi S, Fleming MT, Molina AM, Wolf SP, de Leeuw R, Fernandez C, Kang P, Southwell T, Jones CL, Fernandez E, Kelly WK. Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2020.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

February 20, 2020

Volume

38

Issue

6

Location

San Francisco, CA

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences